deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00878072

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Sponsor: Novartis Pharmaceuticals

Interventions Famciclovir
Updated 9 times since 2017 Last updated: Jun 3, 2021 Started: Mar 25, 2009 Primary completion: Jun 2, 2010 Completion: Jun 2, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00878072, this PHASE2/PHASE3 trial focuses on Herpes Labialis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotCompleted~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotCompleted~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotCompleted~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  4. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2_PHASE3

Show 4 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Jun 2018 — Nov 2020 [monthly]

    Completed PHASE2_PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .